Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renaud Ciappuccini1, Camila Nascimento2, Agathe Edet-Sanson3

  • 1Service de médecine nucléaire et UCP thyroïde, Centre François-Badesse, 3, avenue du Général-Harris, 14000 Caen, France; Inserm 1086 ANTICIPE, BioTICLA, Université de Caen Normandie, 14000 Caen, France.

Bulletin Du Cancer
|November 6, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

EJNMMI research·2026
Same author

The hypothalamic-neurohypophyseal system in preeclampsia: a systematic review with a subgroup meta-analysis of copeptin levels worldwide.

Frontiers in endocrinology·2026
Same author

GMP-compliant automated synthesis and quality control of [<sup>177</sup>Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer.

EJNMMI radiopharmacy and chemistry·2026
Same author

Clinical value of per-treatment whole-body single-time-point automated dosimetry for [<sup>177</sup>Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same author

False-Positive Skin Uptake on 18F-Choline PET/CT Related to an Inflammatory Epidermoid Cyst in a Patient With Parathyroid Adenoma.

Clinical nuclear medicine·2025
Same author

[<sup>123</sup>I]-mIBG and [<sup>18</sup>F]-FDOPA differential uptake in the follow-up of neonatal neuroblastoma.

EJNMMI reports·2025

Nuclear medicine, including Iodine-131 and PET scans, is evolving for thyroid cancer treatment. New theranostic approaches offer personalized medicine for various thyroid cancer types.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceuticals

Background:

  • Nuclear medicine, particularly radioiodine (131I), is a key treatment for differentiated thyroid cancer (DTC) metastases.
  • Refractory DTC and aggressive anaplastic thyroid cancer (ATC) require advanced imaging and treatment strategies.

Purpose of the Study:

  • To review current and emerging nuclear medicine techniques for thyroid cancer management.
  • To explore the role of Iodine-131, PET imaging, and novel theranostic agents in personalized thyroid cancer therapy.

Main Methods:

  • Review of radioiodine therapy (131I) and its guidance via scintigraphy.
  • Utilization of 18F-FDG PET for diagnosis and prognosis in refractory DTC and ATC.
  • Exploration of novel PET tracers (18F-DOPA, 68Ga-DOTATOC, PSMA, FAP) for medullary thyroid cancer (MTC) and theranostics.
Keywords:
Cancer thyroïdienCancers réfractairesImagerie moléculaireIode 131Molecular imagingPETRadioiodineRefractory cancersTEPTheranosticsThyroid cancerThéranostique

Related Experiment Videos

Main Results:

  • 131I remains a cornerstone for RAI-avid DTC metastases.
  • 18F-FDG PET is crucial for refractory DTC and ATC.
  • New theranostic agents like PSMA and FAP show promise for diverse thyroid cancers.

Conclusions:

  • Molecular imaging is shifting thyroid cancer management from a "one-size-fits-all" approach to personalized medicine.
  • Emerging theranostic radiopharmaceuticals offer new avenues for tailored thyroid cancer treatment.